Business Atlas

How Enterprise Is Built
Sign In
Text size
100%
Theme
Companies and Brands

Illumina, Inc.

Health Care

Illumina, Inc. is an American biotechnology company headquartered in San Diego, California, the world's leading maker of DNA sequencing and genetic analysis instruments. It was founded in 1998 and developed sequencing-by-synthesis technology that dramatically increased the speed and lowered the cost of reading DNA compared with earlier methods, playing a central role in reducing the cost of sequencing a human genome from many millions of dollars in the early 2000s to a small fraction of that figure today. Illumina's sequencing systems are used across academic research, clinical diagnostics, agricultural genomics, and pharmaceutical drug development, and the company holds a dominant share of the global next-generation sequencing market it helped create.

Facts
Company Type
Public 1
Founded Year
1998 1
Size Band
10,000 to 99,999 2
Listing
Nasdaq 3
Status
Active 3
Company Type
Company Type (category)
Public 1
Connections

Operates In

A major biotechnology company; classified in the atlas biotechnology-industry.

In the Other Atlases

Located In

Also in Geography Atlas: where this subject is located.

Source Wikipedia: Illumina, Inc.tier 2
Sources
1. Wikipedia: Illumina, Inc.
Wikipedia
  • Infobox: type
    Public
  • Lead section
    Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
View the Source
2. StockAnalysis.com: StockAnalysis company profile for Illumina, Inc.
StockAnalysis.comCompany profile: Employees
Quote, Company profile: Employees
Employees 10,080
View the Source
3. U.S. Securities and Exchange Commission (EDGAR): SEC EDGAR submissions for ILLUMINA, INC.
U.S. Securities and Exchange Commission (EDGAR)
  • exchanges
    "exchanges": [ "Nasdaq" ]
  • tickers
    "tickers": [ "ILMN" ]
View the Source
Wikidata: Illumina, Inc.
Wikidata Q2068984, class allow-list match (w-wdresolver-0926)View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.